Inhaled antibiotics for bronchiectasis: are we there yet?

被引:0
|
作者
Johnson, Chris [1 ]
Haworth, Charles S. [1 ]
机构
[1] Papworth Hosp, Cambridge Ctr Lung Infect, Cambridge CB23 3RE, England
关键词
Bronchiectasis; Nebulised antibiotics; Therapy; Chronic infection; Pseudomonas aeruginosa;
D O I
10.1007/s13665-015-0126-4
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Chronic infection in non-CF bronchiectasis is an important risk factor for disease progression, poor quality life, admission to hospital and perhaps reduced life expectancy. The use of long-term oral and inhaled antibiotics has been included in expert consensus-based guidelines but until recently supporting evidence has been weak. The design, duration and size of adequately powered clinical trials remain challenging, and this has been reflected in some of the reported outcomes. In addition, the tolerability of nebulised antibiotics remains an issue. Despite this, it is now possible to include inhaled antibiotics in treatment strategies and be more specific about antibiotic choice and dose. New inhaled antibiotic options continue to be developed. The most difficult challenge to the success of this intensive treatment will be the promotion of patient adherence.
引用
收藏
页码:198 / 204
页数:7
相关论文
共 50 条
  • [1] Inhaled antibiotics for bronchiectasis: are we there yet?
    Chris Johnson
    Charles S. Haworth
    [J]. Current Pulmonology Reports, 2015, 4 (4) : 198 - 204
  • [2] Oral versus inhaled antibiotics for bronchiectasis
    Spencer, Sally
    Felix, Lambert M.
    Milan, Stephen J.
    Normansell, Rebecca
    Goeminne, Pieter C.
    Chalmers, James D.
    Donovan, Tim
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (03):
  • [3] Safety and tolerability of inhaled antibiotics in patients with bronchiectasis
    Velez-Diaz-Pallares, Manuel
    Montero-Llorente, Beatriz
    Angeles Parro-Martin, Maria
    Martinez-Barros, Hilario
    Maiz Carro, Luis
    Nieto Royo, Rosa
    Gomez-Lozano, Ana
    Menacho-Roman, Miriam
    Alvarez-Diaz, Ana
    [J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 2022, 72
  • [4] A new dawn: inhaled antibiotics for patients with bronchiectasis
    Grimwood, Keith
    Chang, Anne B.
    [J]. LANCET RESPIRATORY MEDICINE, 2019, 7 (03): : 188 - 189
  • [5] Using antibiotics responsibly: are we there yet?
    Dyar, Oliver James
    Obua, Celestino
    Chandy, Sujith
    Xiao, Yonghong
    Lundborg, Cecilia Stalsby
    Pulcini, Celine
    [J]. FUTURE MICROBIOLOGY, 2016, 11 (08) : 1057 - 1071
  • [6] The efficacy of inhaled antibiotics in non-cystic fibrosis bronchiectasis
    Amaro, Rosanel
    Panagiotaraka, Meropi
    Alcaraz, Victoria
    Torres, Antoni
    [J]. EXPERT REVIEW OF RESPIRATORY MEDICINE, 2018, 12 (08) : 683 - 691
  • [7] Randomized Clinical Trials of Inhaled Antibiotics in Bronchiectasis Cause for Optimism?
    Wong, Conroy
    Martinez-Garcia, Miguel Angel
    [J]. CHEST, 2023, 163 (01) : 3 - 5
  • [8] Inhaled corticosteroids and mortality in COPD: are we there yet?
    Stirling, R.
    [J]. THORAX, 2006, 61 (08) : 735 - 735
  • [9] Inhaled Antibiotics: Do as We Say Not as We Study
    Hamblin, Susan
    Smith, Susan
    [J]. CRITICAL CARE MEDICINE, 2018, 46 (01) : 159 - 161
  • [10] Inhaled Antibiotics in Cystic Fibrosis (CF) and Non-CF Bronchiectasis
    Tay, George T. P.
    Reid, David W.
    Bell, Scott C.
    [J]. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 36 (02) : 267 - 286